Rasburicase (Fasturtec®);Rasburicase (Fasturtec®)

Therapeutische Umschau

Volumn 61, Issue 9, 2004, Pages 579-582

  Vogt, Bruno ^a   Gugger, M ^b   Frey, F J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; LOSARTAN; LOSARTAN POTASSIUM; RASBURICASE; RECOMBINANT PROTEIN; URATE OXIDASE; URIC ACID;

CANCER CHEMOTHERAPY; DRUG MECHANISM; GOUT; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; REVIEW; SOLID TUMOR; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CRYSTALLIZATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY TUBULE; URINE;

CRYSTALLIZATION; GLOMERULAR FILTRATION RATE; GOUT; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; RECOMBINANT PROTEINS; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID;

EID: 4544296986     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.9.579     Document Type: Review

References (10)

1. Easton J, Noble S, Jarvis B. Rasburicase. Paediatr Drugs 2001; 3: 433-437; discussion 438-439.
2. Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998; 77: Suppl 4: 18-20.
3. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-4406.
4. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
5. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol 2002; 13: 789-795.
6. Snaith ML: Gout: diet and uric acid. Lancet 2001; 358: 525 (commentary).
7. Wurzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-1860.
8. Phillips M, Hunt RE, Shergy WJ, Hernandez J. Urate oxidase in the treatment of severe tophaceous gout with hyperuricemia refractory to high-dose allopurinol: case report and review. Artritis Rheumatology 2000; 43(suppl 9): S401 (abstr).
9. Rozenberg S, Roche B, Dorent R et al. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995; 62: 392-394.
10. Vogt B, Frey FJ. Urate-oxidase (rasburicase) for the treatment of severe tophaceous gout in a patient with kidney transplant. Swiss Med Wkly 2002; 132: S22 [Abstr].